Takeyama M, Mori K, Morikawa N, Asakura S, Chaen T, Watanabe N, Mogi G
Department of Clinical Pharmacy, Oita Medical University, Japan.
J Pharm Pharmacol. 1994 Jan;46(1):41-5. doi: 10.1111/j.2042-7158.1994.tb03717.x.
Before terfenadine treatment, the mean substance P and vasoactive intestinal polypeptide (VIP) concentrations in nasal secretions from nasal allergy patients tended to be higher than the values of healthy subjects. During terfenadine treatment, the mean substance P concentrations in nasal secretions from patients allergic to house dust or pollen were significantly decreased to 62 and 39% of the initial values, respectively. The mean VIP concentrations in nasal secretions from the house dust allergy patients and the pollen allergy patients were significantly decreased to 52 and 18% of the initial values, respectively. Plasma substance P and VIP concentrations were not affected by nasal allergic symptom and terfenadine treatment.
在特非那定治疗前,鼻过敏患者鼻分泌物中P物质和血管活性肠肽(VIP)的平均浓度往往高于健康受试者的值。在特非那定治疗期间,对屋尘或花粉过敏患者鼻分泌物中P物质的平均浓度分别显著降低至初始值的62%和39%。屋尘过敏患者和花粉过敏患者鼻分泌物中VIP的平均浓度分别显著降低至初始值的52%和18%。血浆P物质和VIP浓度不受鼻过敏症状和特非那定治疗的影响。